A surprising discovery reveals that lubiprostone may help slow the progression of chronic kidney disease. In a clinical trial, patients taking the drug showed a slower decline in kidney function compared to those on placebo.
Researchers link this effect to the gut–kidney axis, where improving gut health reshapes the microbiome and boosts compounds like spermidine, supporting cellular energy systems (mitochondria).
Interestingly, the benefits were not due to toxin reduction but improved gut and cellular function.
This finding opens a promising new direction for CKD treatment, with larger trials planned to confirm the results.
Read more at ScienceDaily
